Atlas Trials

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).

Clinical trial NCT02143882 · COMPLETED

Trial details

NCT number
NCT02143882
Sponsor
Public Health England
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Live Attenuated Influenza Vaccine
Start date
2014-09-01
Primary completion
2017-03-31
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.